DURECT

1 follower

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program.

Industries

Employees

51-200

Links


Org chart

James E. Brown
President & CEO
Collapse
Judy Joice
SVP, Operations & Corporate Quality Assurance
Weiqi Lin
EVP, Research & Development & Principal Scientist
Charlie Claycomb
Executive Director Information Technology
Steve Helmer
Vice President, Chief Patent Counsel

Board & advisors

Peter Garcia
Director
Gail J. Maderis
Chair of the Board